Disease graft versus host

Grafting of polymers Graft polymerization Graft versus host disease Grahamite Graham s salt Grain... 

The red cells also may be filtered to reduce the white cell content. This technique is needed if there is a chance of the patient developing graft versus host disease (GvHD), ie, transfused white cells attack the cells of the patient. 

Contamination of blood products with lymphocytes can lead to transfusion-induced reactions ranging from a mild fever to severe reactions such as alloimmunization and graft versus host disease (GvHD), in which the transfused lymphocytes (graft) survive the defensive immune reaction of the patient (host) and start a reaction which destroys the cells of the host. The patient also may develop an immune response to the human leukocyte antigen (HLA) type of the graft s cells and reject all platelet transfusions that do not match their own HLA system. The HLA system, found on blood platelets and lymphocytes, is more compHcated than, but similar to, the ABO blood group system of red cells. 

GTPase Guanidine triphosphatase GVHD Graft-versus-host-disease GVHR Graft-versus-host-reaction... 

Graft-versus-host disease Hormone therapy... 

Voriconazole is started in the patient along with 1 mg/kg per day of methylprednisolone to control the graft-versus-host disease. Her tacrolimus dose was also decreased by 70% with the addition of voriconazole and a recent tacrolimus blood level of 1 0 ng/mL. Unfortunately, the patient remains febrile with worsening respiratory pain. A repeat CT scan of the lung demonstrates new nodules, and pleural effusion in the right lung. 

Explain graft-versus-host disease (GVHD). 

Recommend a prophylactic and treatment regimen for graft-versus-host disease (GVHD). 

Graft-versus-host disease (GVHD) is caused by the activation of donor lymphocytes leading to immune damage to the skin, gut, and fiver in the recipient. An immunosuppressive regimen is administered to prevent GVHD in recipients... 

Treatment of Acute Graft-Versus-Host Disease... 

Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host disease Pathophysiology, clinical manifestations, and management. Cancer 2004 101 1936-1946. 

Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005 11 945-956. 

Graft-versus-host disease Failure of a recipient s body to accept a transplanted tissue or organ as the result of immunologic incompatibility immunologic resistance to foreign tissue. 

Wysocki CA, Jiang Q, Panoskaltsis-Mortari A, et al. Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood 2005 106 3300-3307. 

Bland, P.W. and Whiting, C.V. (1992) Induction of MHC class II gene products in rat intestinal epithelium during graft-versus-host disease and effects on the immune function of the epithelium. Immunology 75, 366-371. 

MacDonald, T.T. and Ferguson, A. (1977) Hypersensitivity reactions in the small intestine. III. The effects of allograft rejection and of graft-versus-host disease on epithelial cell kinetics. Cell and Tissue Kinetics 10, 301-312. 

Solomon, S.R., Mielke, S., Savani, B.N., Montero, A., Wisch, L., Childs, R., Hensel, N., Schindler, J., Ghetie, V., Leitman, S.F., Mai, T., Carter, C.S., Kurlandcr, R., Read, E.J., Vitetta, E.S., and Barrett, A.J. (2005) Selective depletion of alloreactive donor lymphocytes A novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 106,1123-1129. 

In general, immunosuppression, expansion of regulatory cells, costimulatory blockade, or promotion of a Th2 cytokine milieu is considered to be supportive of disease control in T-cell regulatory disorders such as autoimmune disease and graft-versus-host disease (GvHD) [2]. In contrast, killer cells, a Thl cytokine milieu, or activated lymphocyte infusions support control of malignancy and infections. Maintaining a balance between the two... 

Remberger M, Ringden 0, Blau IW et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood. 2001 98 1739-1745. 

---